Mihaela S Stefan1, Raveendhara R Bannuru2, Darleen Lessard3, Joel M Gore4, Peter K Lindenauer5, Robert J Goldberg3. 1. Department of General Medicine, Baystate Medical Center, Springfield, MA; Tufts Clinical and Translational Science Institute, Tufts University School of Medicine, Boston, MA. Electronic address: mihaela.stefan@bhs.org. 2. Tufts Clinical and Translational Science Institute, Tufts University School of Medicine, Boston, MA. 3. Department of Quantitative Health Sciences, Worcester, MA; University of Massachusetts Medical School, Worcester, MA. 4. Department of Medicine, Worcester, MA; University of Massachusetts Medical School, Worcester, MA. 5. Department of General Medicine, Baystate Medical Center, Springfield, MA; Tufts Clinical and Translational Science Institute, Tufts University School of Medicine, Boston, MA.
Abstract
BACKGROUND: There are limited data describing contemporary trends in the management and outcomes of patients with COPD who develop acute myocardial infarction (AMI). METHODS: The study population consisted of patients hospitalized with AMI at all greater Worcester, Massachusetts, medical centers between 1997 and 2007. RESULTS: Of the 6,290 patients hospitalized with AMI, 17% had a history of COPD. Patients with COPD were less likely to be treated with β-blockers or lipid-lowering therapy or to have undergone interventional procedures during their index hospitalization than patients without COPD. Patients with COPD were at higher risk for dying during hospitalization (13.5% vs 10.1%) and at 30 days after discharge (18.7% vs 13.2%), and their outcomes did not improve during the decade-long period under study. After multivariable adjustment, the adverse effects of COPD remained on both in-hospital (OR, 1.25; 95% CI, 0.99-1.50) and 30-day all-cause mortality (OR, 1.31; 95% CI, 1.10-1.58). The use of evidence-based therapies for all patients with AMI increased between 1997 and 2007, with a particularly marked increase for patients with COPD. CONCLUSIONS: Our results suggest that the gap in medical care between patients with and without COPD hospitalized with AMI narrowed substantially between 1997 and 2007. Patients with COPD, however, remain less aggressively treated and are at increased risk for hospital adverse outcomes than patients without COPD in the setting of AMI. Careful consideration is necessary to ensure that these high-risk complex patients are not denied the benefits of effective cardiac therapies.
BACKGROUND: There are limited data describing contemporary trends in the management and outcomes of patients with COPD who develop acute myocardial infarction (AMI). METHODS: The study population consisted of patients hospitalized with AMI at all greater Worcester, Massachusetts, medical centers between 1997 and 2007. RESULTS: Of the 6,290 patients hospitalized with AMI, 17% had a history of COPD. Patients with COPD were less likely to be treated with β-blockers or lipid-lowering therapy or to have undergone interventional procedures during their index hospitalization than patients without COPD. Patients with COPD were at higher risk for dying during hospitalization (13.5% vs 10.1%) and at 30 days after discharge (18.7% vs 13.2%), and their outcomes did not improve during the decade-long period under study. After multivariable adjustment, the adverse effects of COPD remained on both in-hospital (OR, 1.25; 95% CI, 0.99-1.50) and 30-day all-cause mortality (OR, 1.31; 95% CI, 1.10-1.58). The use of evidence-based therapies for all patients with AMI increased between 1997 and 2007, with a particularly marked increase for patients with COPD. CONCLUSIONS: Our results suggest that the gap in medical care between patients with and without COPD hospitalized with AMI narrowed substantially between 1997 and 2007. Patients with COPD, however, remain less aggressively treated and are at increased risk for hospital adverse outcomes than patients without COPD in the setting of AMI. Careful consideration is necessary to ensure that these high-risk complex patients are not denied the benefits of effective cardiac therapies.
Authors: Deepak L Bhatt; Matthew T Roe; Eric D Peterson; Yun Li; Anita Y Chen; Robert A Harrington; Adam B Greenbaum; Peter B Berger; Christopher P Cannon; David J Cohen; C Michael Gibson; Jorge F Saucedo; Neal S Kleiman; Judith S Hochman; William E Boden; Ralph G Brindis; W Frank Peacock; Sidney C Smith; Charles V Pollack; W Brian Gibler; E Magnus Ohman Journal: JAMA Date: 2004-11-03 Impact factor: 56.272
Authors: Spyridon Liosis; Timm Bauer; Rudolf Schiele; Helmut Gohlke; Martin Gottwik; Hugo Katus; Georg Sabin; Ralf Zahn; Steffen Schneider; Bernhard Rauch; Jochen Senges; Uwe Zeymer Journal: Clin Res Cardiol Date: 2013-06-06 Impact factor: 5.460
Authors: Wassim W Labaki; Carlos H Martinez; Fernando J Martinez; Craig J Galbán; Brian D Ross; George R Washko; R Graham Barr; Elizabeth A Regan; Harvey O Coxson; Eric A Hoffman; John D Newell; Douglas Curran-Everett; James C Hogg; James D Crapo; David A Lynch; Ella A Kazerooni; MeiLan K Han Journal: Am J Respir Crit Care Med Date: 2017-12-01 Impact factor: 21.405
Authors: Jamuna K Krishnan; Mangala Rajan; Samprit Banerjee; Sonal G Mallya; MeiLan K Han; David M Mannino; Fernando J Martinez; Monika M Safford Journal: Ann Am Thorac Soc Date: 2022-10
Authors: Mihaela S Stefan; Meng-Shiou Shieh; Penelope S Pekow; Michael B Rothberg; Jay S Steingrub; Tara Lagu; Peter K Lindenauer Journal: J Hosp Med Date: 2013-01-18 Impact factor: 2.960
Authors: Mihaela S Stefan; Michael B Rothberg; Aruna Priya; Penelope S Pekow; David H Au; Peter K Lindenauer Journal: Thorax Date: 2012-08-31 Impact factor: 9.139
Authors: Mihaela S Stefan; Brian H Nathanson; Tara Lagu; Aruna Priya; Penelope S Pekow; Jay S Steingrub; Nicholas S Hill; Robert J Goldberg; David M Kent; Peter K Lindenauer Journal: Ann Am Thorac Soc Date: 2016-07